E5768
Monoclonal Anti-Eotaxin-2 antibody produced in mouse
clone 61016.11, purified immunoglobulin, lyophilized powder
Synonym(s):
Anti-MPIF-2
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Conjugate:
unconjugated
Clone:
61016.11, monoclonal
Application:
capture ELISA
neutralization
western blot
neutralization
western blot
Species reactivity:
human
Citations:
8
Technique(s):
capture ELISA: suitable
neutralization: suitable
western blot: 1-2 μg/mL
neutralization: suitable
western blot: 1-2 μg/mL
Uniprot accession no.:
Product Name
Monoclonal Anti-Eotaxin-2 antibody produced in mouse, clone 61016.11, purified immunoglobulin, lyophilized powder
biological source
mouse
conjugate
unconjugated
antibody form
purified immunoglobulin
antibody product type
primary antibodies
clone
61016.11, monoclonal
form
lyophilized powder
species reactivity
human
technique(s)
capture ELISA: suitable
neutralization: suitable
western blot: 1-2 μg/mL
isotype
IgG1
UniProt accession no.
storage temp.
−20°C
target post-translational modification
unmodified
Quality Level
Gene Information
human ... CCL24(6369)
Analysis Note
The antibody neutralizes the biological activity of recombinant human eotaxin-2. It exhibits less than 0.03% cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.
Application
Anti-eotaxin-2 antibody may be used for neutralization assays at a working concentration of 1-5 μg/ml in the presence of 100 ng/ml of human recombinant eotaxin-2. The antibody is suitable for immunoblotting at 1-2 μg/ml concentration. For capture ELISA, a final concentration of 2 μg/ml may be used.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
General description
Accumulation of eosinophils is the hallmark of several medical conditions such as infections and systemic diseases. A number of chemokines stimulate the proliferation, migration and accumulation of eosinophils at the site of inflammation. Eotaxin-2 is chemoattractant that selectively acts on eosinophils and has minimal effect on other leukocytes. It is secreted in response to TNF-α, IL-5 or IL-3. The effect of Eotaxin is mediated by specific eotaxin receptor that induces activation of Gi proteins, MAPK signaling and involves changes in intracellular calcium levels and cytoskeletal reorganization. Eotaxin receptor is present on eosinophils, basophils and T-helper cells. Eotaxin coordinates the accumulation of these cells in response to allergic inflammation and homing of eosinophils to gastrointestinal tract and mucosal tissues
Monoclonal Anti-Eotaxin-2 (MPIF-2) recognizes recombinant human eotaxin-2, less than 0.03 % cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.
Monoclonal Anti-Eotaxin-2 (MPIF-2) recognizes recombinant human eotaxin-2, less than 0.03 % cross-reactivity with recombinant human eotaxin, MIP-1α, and MCP-3.
Immunogen
recombinant human eotaxin-2.
Physical form
Lyophilized from a 0.2 μm filtered solution in phosphate buffered saline
Preparation Note
Purified using protein G
Not finding the right product?
Try our Product Selector Tool.
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells
Sallusto F et al
Science, 2777, 2005-2007 (1997)
Intracellular localization and release of eotaxin from normal eosinophils
Nakajima T et al
Febs Letters, 343, 226-230 (1998)
A Mishra et al.
The Journal of clinical investigation, 103(12), 1719-1727 (1999-06-22)
The histological identification of increased eosinophils in the gastrointestinal tract occurs in numerous clinical disorders; however, there is a limited understanding of the mechanisms regulating eosinophil trafficking into this mucosal surface. The results presented in this study characterize the processes
The p38 MAP kinase and myosin light chain kinase (MLCK) critically regulate eosinophil chemotaxis in response to eotaxin
Alam R et al
The Journal of Allergy and Clinical Immunology, 103, S56-S56 (1999)
Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues.
M E Rothenberg
American journal of respiratory cell and molecular biology, 21(3), 291-295 (1999-08-26)
Related Content
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service